HIF1AN — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2219244	0.60	12/20
SCHEMBL996838	0.57	11/20
SCHEMBL996840	0.57	11/20
SCHEMBL996376	0.53	9/20
SCHEMBL996379	0.53	9/20
SCHEMBL997051	0.51	9/20
SCHEMBL997056	0.51	9/20
SCHEMBL995975	0.51	9/20
SCHEMBL996364	0.51	9/20
SCHEMBL998657	0.51	9/20
SCHEMBL998658	0.51	9/20
SCHEMBL998575	0.48	9/20
SCHEMBL998577	0.48	9/20
SCHEMBL998194	0.54	8/20
SCHEMBL998195	0.54	8/20
SCHEMBL998221	0.54	8/20
SCHEMBL998223	0.54	8/20
SCHEMBL997737	0.48	7/20
SCHEMBL997739	0.48	7/20
SCHEMBL997043	0.48	6/20

Clinical trials — most relevant to HIF1AN by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.	PHASE3	COMPLETED
Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Carnosine for Peripheral Vascular Disease	PHASE2	UNKNOWN
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer	PHASE2	UNKNOWN
Study of the Effects of Iron on Lung Blood Pressure at High Altitude	PHASE2	WITHDRAWN
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)	PHASE2	UNKNOWN
Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients	PHASE1/PHASE2	RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients	PHASE1/PHASE2	RECRUITING
First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer	PHASE2	COMPLETED
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas	PHASE2	COMPLETED
Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment	PHASE1	COMPLETED
Repeat Dose Safety Study for Compound to Treat Anemia	PHASE1	COMPLETED
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases	PHASE1	COMPLETED
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)	PHASE1	COMPLETED
EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors	PHASE1	COMPLETED
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a	PHASE1	COMPLETED
Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery	nan	COMPLETED
TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer	nan	UNKNOWN
Mitochondrial Function of Immune Cells in Sepsis	nan	COMPLETED
Study of the Effects of Iron Levels on the Lungs at High Altitude	nan	COMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock	nan	COMPLETED
Hypoxia-induced Autophagy in the Pathogenesis of MAP	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HIF1AN binder may also engage these)

Protein	Name	Similarity
Q8BLR9	—	1.000	Q8BLR9 →
P59723	—	0.993	P59723 →
Q3TA59	—	0.959	Q3TA59 →
A2RUC4	—	0.958	A2RUC4 →
Q6AY40	—	0.952	Q6AY40 →
RIOX2	Ribosomal oxygenase 2	0.951	landscape →
E1C7T6	—	0.951	E1C7T6 →
Q5F361	—	0.949	Q5F361 →
Q9UK99	—	0.949	Q9UK99 →
A2RSX7	—	0.947	A2RSX7 →
Q5IH13	—	0.947	Q5IH13 →
A6H7H7	—	0.946	A6H7H7 →
Q28C34	—	0.946	Q28C34 →
MALT1	Mucosa-associated lymphoid tissue lymphoma translocation protein 1	0.946	landscape →
Q8BM85	—	0.946	Q8BM85 →
Q5R673	—	0.945	Q5R673 →
Q9TS33	—	0.945	Q9TS33 →
Q8W519	—	0.945	Q8W519 →
Q8TEA7	—	0.945	Q8TEA7 →
Q6NYU2	—	0.945	Q6NYU2 →
Q9M9Y8	—	0.944	Q9M9Y8 →
Q9MBC2	—	0.944	Q9MBC2 →
Q9DC63	—	0.943	Q9DC63 →
Q08BV2	—	0.943	Q08BV2 →
A2AGL3	—	0.943	A2AGL3 →
Q15413	—	0.943	Q15413 →
P30957	—	0.943	P30957 →
Q8N6S4	—	0.943	Q8N6S4 →
RYR2	Ryanodine receptor 2	0.943	landscape →
E9PZQ0	—	0.942	E9PZQ0 →